ArticlePharmaceutics2022

Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines.

Pablo García-Molina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.